Fair Value Calculator Fair Value Calculator
EN DE

IOLCP (IOLCP) Fair Value & Analysis

Healthcare · Market cap ₹44.1B

I IOLCP IOLCP · NSE
Price₹150.31
Fair Value₹103.16
Upside-31.4%
Quality70/100
Watch IOLCP for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹54.45 – ₹128.95

Fair value as of: Jul 3, 2026

From 26 valuation models · updated today

Share price +14.9% over the past month.

Price vs Fair Value (12 months)

₹150.31 ₹67.98 Fair Value ₹103.16 Jun 2025 Jul 2026

12‑month range ₹67.98 – ₹150.31 · fair‑value band ₹54.45 – ₹128.95 · the ₹150.31 price screens above the ₹103.16 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

IOLCP (IOLCP) currently trades at ₹150.31, while our model-based Fair Value estimate is ₹103.16 — implying the stock looks roughly 31.4% overvalued today. We read business quality at 70/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, IOLCP generated revenue of ₹23.2B at a net margin of 5.9%. Revenue grew 17.4% year over year. It earns a return on equity of 7.9%. The balance sheet holds a net cash position of ₹629M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) ₹23.2B
Revenue growth (YoY) +17.4%
Net margin 5.9%
Return on equity 7.9%
Free cash flow ₹384M FY2026
P/E ratio 32.0
More key figures
Operating margin 11.7%
EPS (TTM) ₹4.70
Dividend yield 0.7%
EPS growth (YoY) +69.7%
Net cash ₹629M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

IOLCP reported revenue of ₹23.2B in FY2026 versus ₹21.8B in FY2022, a compound +1.5%/yr. Reported net income was ₹1.4B in FY2026, compounding −4.8%/yr from FY2022.

Revenue +1.5%/yr
FY22 ₹21.8B
FY23 ₹22.0B
FY24 ₹21.2B
FY25 ₹20.7B
FY26 ₹23.2B
Net income −4.8%/yr
FY22 ₹1.7B
FY23 ₹1.4B
FY24 ₹1.3B
FY25 ₹1.0B
FY26 ₹1.4B

Is IOLCP fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock Price Fair Value vs Fair Value
1276 1276 HK$57.85 HK$29.84 -48%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.08 ¥26.59 -44%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,786 ₹991.46 -44%
Zoetis Inc Z1TS34 R$26.19 R$26.01 -1%
Hansoh Pharmaceutical Group 3692 HK$29.30 HK$23.90 -18%
Divi's Laboratories Limited DIVISLAB ₹6,639 ₹1,281 -81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is IOLCP (IOLCP) undervalued?
As of Jul 3, 2026, our model estimates a fair value of ₹103.16 versus a price of ₹150.31 — about −31% (overvalued). Model-based estimate, not financial advice.
What is the fair value of IOLCP?
Our model-based fair value for IOLCP is ₹103.16 (as of Jul 3, 2026), built from audited fundamentals. The current price is ₹150.31.
What is the quality score of IOLCP?
IOLCP has a Quality Score of 70/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of IOLCP (IOLCP)?
IOLCP reported trailing-twelve-month revenue of about ₹23.2B (latest available figure, as of Jul 3, 2026).
What is the net profit margin of IOLCP?
The net profit margin of IOLCP is about 5.9%, meaning it keeps roughly 5.9% of revenue as net income. Based on the latest reported figures.
Does IOLCP pay a dividend?
IOLCP currently shows a dividend yield of about 0.68% relative to its recent price (as of Jul 3, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.